title: Comparison of 18F-FDG and PiB PET in cognitive impairment.
abstract: The purpose of this study was to compare the diagnostic accuracy of glucose metabolism and amyloid deposition as demonstrated by (18)F-FDG and Pittsburg Compound B (PiB) PET to evaluate subjects with cognitive impairment.
  
  
  METHODS
  Subjects were selected from existing participants in the Mayo Alzheimer's Disease Research Center or Alzheimer's Disease Patient Registry programs. A total of 20 healthy controls and 17 amnestic mild cognitive impairment (aMCI), 6 nonamnestic mild cognitive impairment (naMCI), and 13 Alzheimer disease (AD) subjects were imaged with both PiB and (18)F-FDG PET between March 2006 and August 2007. Global measures for PiB and (18)F-FDG PET uptake, normalized to cerebellum for PiB and pons for (18)F-FDG, were compared. Partial-volume correction, standardized uptake value (SUV), and cortical ratio methods of image analysis were also evaluated in an attempt to optimize the analysis for each test.
  
  
  RESULTS
  Significant discrimination (P < 0.05) between controls and AD, naMCI and aMCI, naMCI and AD, and aMCI and AD by PiB PET measurements was observed. The paired groupwise comparisons of the global measures demonstrated that PiB PET versus (18)F-FDG PET showed similar significant group separation, with only PiB showing significant separation of naMCI and aMCI subjects.
  
  
  CONCLUSIONS
  PiB PET and (18)F-FDG PET have similar diagnostic accuracy in early cognitive impairment. However, significantly better group discrimination in naMCI and aMCI subjects by PiB, compared with (18)F-FDG, was seen and may suggest early amyloid deposition before cerebral metabolic disruption in this group.
authors.affiliation: Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA. vlowe@mayo.edu
authors.forename: Val J
authors.initials: VJ
authors.lastname: Lowe
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Kemp
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Jack
authors.forename: Matthew
authors.initials: M
authors.lastname: Senjem
authors.forename: Stephen
authors.initials: S
authors.lastname: Weigand
authors.forename: Maria
authors.initials: M
authors.lastname: Shiung
authors.forename: Glenn
authors.initials: G
authors.lastname: Smith
authors.forename: David
authors.initials: D
authors.lastname: Knopman
authors.forename: Bradley
authors.initials: B
authors.lastname: Boeve
authors.forename: Brian
authors.initials: B
authors.lastname: Mullan
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Petersen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging; D000814:Aniline Compounds; D003072:Cognition Disorders / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D019275:Radiopharmaceuticals; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18